Evidence map›Paper›PMID 40438577›Full record

ArticleFrontiers in neurology2025

Biomarker identification associated with M2 tumor-associated macrophage infiltration in glioblastoma.

Xue-Yuan Li, Zhi-Yun Yu, Hong-Jiang Li, Dong-Ming Yan, Chao Yang, Xian-Zhi Liu

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xue-Yuan Li *Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhi-Yun Yu *Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hong-Jiang Li *Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dong-Ming YanDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chao YangDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xian-Zhi LiuDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: M2 phenotype tumor-associated macrophages (TAMs) can promote tumor growth, invasion, chemotherapy resistance and so on, leading to malignant progression. The aim of this study was to identify novel prognostic profiles in glioblastoma (GBM) by integrating single-cell RNA sequencing (scRNA-seq) with bulk RNA-seq. Methods: We identified M2-associated genes by intersecting TAM marker genes derived from scRNA-seq with macrophage module genes from WGCNA RNA-seq data. Prognostic M2 TAM-related genes were determined using univariate Cox and LASSO regression analyses. In the following steps, prognostic characteristics, risk groups, and external validation were constructed and validated. The immune landscape of patients with GBM was examined by evaluating immune cells, functions, evasion scores, and checkpoint genes. Results: Analysis of scRNA-seq and bulk-seq data revealed 107 genes linked to M2 TAMs. Using univariate Cox and LASSO regression, 16 genes were identified as prognostic for GBM, leading to the creation and validation of a prognostic signature for GBM survival prediction. Conclusion: Our findings reveal the immune landscape of GBM and enhance understanding of the molecular mechanisms associated with M2 TAMs.

Indexed as

glioblastomaimmune landscapeprognostic signaturesingle celltumor-associated macrophage

Identifiers

PMID40438577
PMCPMC12117037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.